Mylan (MYL) Receives FDA Approval for Generic Version of Takeda's Actoplus Met
Bloomberg reporting Mylan (NYSE: MYL) has won FDA approval for its generic version of Takeda's actoplus met.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan to Present at Goldman Sachs 37th Annual Global Healthcare Conference
- Needham & Company Raises Price Target on Flexion Therapeutics (FLXN) to $34
- Minerva Neurosciences (NERV) Rips 200% Higher on Positive Phase MIN-117 Trial Results
Create E-mail Alert Related CategoriesFDA, Rumors
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!